|
|
Kam |
|
Dhaliwal |
|
Global VP Strategic Alliances |
Bit.bio |
https://proventainternational.com/wp-content/uploads/2022/01/kam-dhaliwal.jpeg |
|
|
|
Asif |
|
Ahmed |
|
Executive Chairman and CEO |
MirZyme Therapeutics |
https://proventainternational.com/wp-content/uploads/2019/12/Asif-Ahmed-New.jpg |
Professor Asif Ahmed is a world-renowned vascular scientist, who established Aston Medical School and is the founder of MirZyme Therapeutics, a biopharmaceutical company developing diagnostics and drugs to address the unmet medical needs and prevent disorders of pregnancy. He discovered two protective pathways that put the ‘brakes’ on preeclampsia; a life-threatening condition in pregnancy. He has championed social mobility, international connectivity and translational research. Before becoming the inaugural Pro-Vice-Chancellor for Health in 2012, he was the Gustav Born Chair of Vascular Biology at the University of Edinburgh. He is the recipient of the 7th British Muslim Awards for ‘Services to Education’ in 2019.
Founder of MirZyme Therapeutics with globally granted patents to prevent preeclampsia. Discoverer of two protective pathways to stop preeclampsia during pregnancy. Founder of the most socially inclusive medical school in the United Kingdom.
Professor Ahmed is a research-minded visionary communicator and possesses entrepreneurial energy and the ability to identify opportunities for growth. He helps to shape the future direction of organisations with his ability to empower others and encourage them to make meaningful contributions to the organisation and wider society.
Most of Professor Ahmed’s academic life was spent in top research-intensive universities. He moved to Aston to bring about a transformational change in Birmingham by establishing the most socially inclusive medical school in the United Kingdom. He wanted to ensure that the school had innovative medical education, inclusive leadership, and a focus on research at the core of its model, but did not compromise entry standards in selecting students from hard-to-reach backgrounds. His message to his medical school staff was simple “Inspire to Aspire”.
Professor Ahmed’s drive is to ensure that his discoveries translate so that no woman who chooses to have a baby ever needs to fear the silent killer preeclampsia. MirZyme and Professor Ahmed are leading a targeted therapeutic approach to prevent preeclampsia. |
|
|
Lassina |
|
Badolo |
|
Executive Director – Head of DMPK, Early Respiratory & Immunology |
AstraZeneca |
https://proventainternational.com/wp-content/uploads/2020/01/Lassina-Badolo.jpg |
Mr. Lassina Badolo graduated from the Free University of Brussels where he took his Ph.D. in Analytical Chemistry and in vitro Toxicology. After a brief Post-Doc in Strasbourg, he joined Lundbeck AS (Denmark) and worked in preclinical DMPK for 6 years followed by 12 years in Discovery DMPK. Lassina has more than 20 years of experience in DMPK from the pharma industry and academia (as an Associate Professor from the University of Copenhagen). Lassina Badolo has over the years had increasing responsibility and is currently director of Discovery NCE Drug Disposition at Merck KgaA in Darmstadt. He has published more than 30 papers. |
|
|
Muireann |
|
Coen |
|
Director, Oncology Discovery Safety Science |
AstraZeneca |
https://proventainternational.com/wp-content/uploads/2022/03/Muireann-Coen.jpg |
Dr. Muireann Coen is a Director of Oncology Discovery Safety Science at AstraZeneca and a Senior Lecturer in the Department of Surgery and Cancer at Imperial College London. She has recently completed the Academy of Medical Sciences FLIER leadership programme.
Her academic research has involved the development and application of metabolic phenotyping and associated bioinformatic strategies in the field of pre-clinical and clinical hepatotoxicity to further mechanistic understanding of toxicity and ultimately identify translational biomarkers. At AstraZeneca she works on discovery stage projects to apply both traditional and new tools to better identify, define and mitigate safety risks for new targets in the oncology pipeline.
Dr. Coen has published over 75 peer-reviewed papers, is an editorial board member of the British Journal of Pharmacology and Nature Scientific Reports and a member of the British Toxicology Society Scientific Sub-Committee and MRC ITTP committee. She was awarded the BTS early career researcher prize in 2010 and an MRC Integrative Toxicology Training Partnership (ITTP) career development fellowship in 2009. |
|
|
Klaus |
|
Dembowsky |
|
Chief Executive Officer |
AMCURE GmbH |
https://proventainternational.com/wp-content/uploads/2020/08/Klaus-Dembowsky_Amcure-Edited.png |
Dr. Klaus Dembowsky has been Chief Executive Officer(CEO) of Amcure since 2015. He has over 25 years of experience in research and development for pharmaceutical and biotech companies and a track record of successfully bringing innovative drugs into clinical development and to the market. He worked for more than 10 years at Bayer’s research institute and served in different management positions in the biotech industry, as Vice President, Drug Discovery at Ingenium Pharmaceuticals, Managing Director at Speedel Experimenta, and Chief Medical Officer at Polyphor. Dr. Dembowsky received his medical degree from the University of Heidelberg and habilitated in neurophysiological research in 1988. |
|
|
Vishal |
|
Sahni |
|
Director, Corporate Business Development & Strategy |
Lundbeck |
https://proventainternational.com/wp-content/uploads/2022/05/Vishal-Sahni-1.jpg |
Vishal is a Director of Corporate Business Development and Strategy at H. Lundbeck A/S where he focuses on searching and evaluating pre-clinical, clinical and digital opportunities for partnering. Over the last 10+ years, Vishal led teams at several stages of the drug discovery, development and commercialization value chain at Eisai, GSK and MSD, working across Europe, the United States and Asia to support the development of small molecule-, biologics- and gene therapy-medicines.
Vishal holds a PhD in Developmental Neurobiology from University College London, a Master’s degree in Experimental Neuroscience from Imperial College London and a Bachelor’s degree in Biomedical Science from King’s College London. |
|
|
Tarek |
|
Samad |
|
Senior Vice President & Global Head, Research |
LUNDBECK |
https://proventainternational.com/wp-content/uploads/2022/01/Tarek-Samad.jpg |
Tarek Samad, Ph.D., is Senior Vice President and Global Head of Research at Lundbeck. He has over two decades of experience in academia and industry, leading small molecule and antibody biologic programs into the clinic. Prior to joining Lundbeck, Dr. Samad was the chief scientific officer at Immunitas Therapeutics and Head of Multiple Sclerosis and Neuroimmunology Research at Sanofi, overseeing a portfolio spanning from early discovery to phase 2 clinical stage. Before joining Sanofi, Tarek was Head of Neurodegeneration Research, and Neuroinflammation Research at Pfizer. |
|
|
Magnus |
|
Walter |
|
Senior Research Fellow, Head of Discovery Chemistry, Screening Biology and Operations |
ABBVIE |
https://proventainternational.com/wp-content/uploads/2022/01/Magnus-Walter.jpg |
Magnus Walter received a Master’s degree in Chemistry from the University of Bonn in Germany and a doctorate from the University of Oxford for his work on resistance against ß-lactam antibiotics. After starting his industrial career at Zeneca in 1998 as chemistry team leader he has worked for Eli Lilly since 2001 based at Lilly’s Erl Wood Research Centre in the UK. In 2012 he became Head of Department at Lilly’s UK Research Centre leading a group of approximately one hundred chemists focused on drug discovery in the areas of neurodegeneration, pain and endocrinology. Since 2014 he is Chief Scientific Officer in Medicinal Chemistry with global portfolio responsibility of Lilly’s chemistry research in the area of Neurodegeneration. |
|
|
Jonathan |
|
Wingfield |
|
Principal Scientist, Mechanistic Structure and Biophysics, Discovery Sciences, R&D |
AstraZeneca |
https://proventainternational.com/wp-content/uploads/2022/01/jonathan-wingfield.jpeg |
Dr. Jonathan Wingfield has almost 30 years of early drug discovery experience with international pharma. Joined AstraZeneca in 2000 as part of the Oncology organisation to deliver technology solutions to drive business change. Involved with the delivery of acoustic technology to revolutionize compound management within screening groups. Moved into Discovery Sciences when it formed in 2010 to continue to drive technology development to the wider AZ organization. In 2015, collaborated with two companies to deliver an innovative high throughput mass spectrometry platform, 30 times faster than the leading commercial ESI MS system. Currently an executive board member of the Society for Laboratory Automation and Screening. |
Radisson Blu Hotel, Stansted Airport
Payment Securely powered by stripe
